Enwei Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	875.47	896.64	808.19	781.2	687.5	675.79
Other Revenue	4.14	4.14	3.94	3.99	4.07	3.91
Revenue	879.6	900.77	812.13	785.19	691.57	679.7
Revenue Growth (YoY)	6.60%	10.91%	3.43%	13.54%	1.75%	7.18%
Cost of Revenue	429.13	453.37	404.17	384.36	346.2	298.67
Gross Profit	450.47	447.41	407.96	400.83	345.37	381.03
Selling, General & Admin	374.68	370.52	342.52	292.84	258.17	264.71
Research & Development	5.55	5.52	9.07	16.82	7.52	4.32
Other Operating Expenses	12.16	11.27	12.56	10.89	9.89	11.64
Operating Expenses	393.52	388.4	365.98	320.45	277.06	281.34
Operating Income	56.96	59	41.98	80.38	68.31	99.69
Interest Expense	-2.31	-2.56	-2.43	-	-	-
Interest & Investment Income	8.11	8.34	7.59	10.3	1.99	0.52
Other Non Operating Income (Expenses)	-0.79	-0.99	-0.08	-0.66	-0.27	-0.88
EBT Excluding Unusual Items	61.97	63.79	47.07	90.03	70.03	99.33
Gain (Loss) on Sale of Investments	-4.32	-4.32	-	-	-	-0.44
Gain (Loss) on Sale of Assets	-0.14	-0.14	-0.26	-0.04	-	-
Asset Writedown	-3.22	-0.2	-0.05	-	-	-0.01
Other Unusual Items	5.76	5.03	-0.06	11.33	11.83	20.25
Pretax Income	60.06	64.16	46.68	101.31	81.86	119.13
Income Tax Expense	11.92	12.22	9.19	15	14.06	17.39
Earnings From Continuing Operations	48.14	51.94	37.5	86.31	67.8	101.73
Net Income	48.14	51.94	37.5	86.31	67.8	101.73
Net Income to Common	48.14	51.94	37.5	86.31	67.8	101.73
Net Income Growth	6.09%	38.53%	-56.56%	27.30%	-33.36%	3.03%
Shares Outstanding (Basic)	104	103	101	103	84	78
Shares Outstanding (Diluted)	104	103	101	103	84	78
Shares Change (YoY)	3.34%	2.06%	-1.82%	21.93%	8.34%	6.51%
EPS (Basic)	0.46	0.50	0.37	0.84	0.80	1.31
EPS (Diluted)	0.46	0.50	0.37	0.84	0.80	1.31
EPS Growth	2.67%	35.73%	-55.75%	4.40%	-38.49%	-3.27%
Free Cash Flow	24.57	53.21	28.69	-50.04	38.8	49.36
Free Cash Flow Per Share	0.24	0.52	0.28	-0.49	0.46	0.63
Dividend Per Share	0.680	0.680	0.180	0.540	1.600	-
Dividend Growth	277.78%	277.78%	-66.70%	-66.22%	-	-
Gross Margin	51.21%	49.67%	50.23%	51.05%	49.94%	56.06%
Operating Margin	6.48%	6.55%	5.17%	10.24%	9.88%	14.67%
Profit Margin	5.47%	5.77%	4.62%	10.99%	9.80%	14.97%
Free Cash Flow Margin	2.79%	5.91%	3.53%	-6.37%	5.61%	7.26%
EBITDA	103.36	105.16	87.2	115.13	99.22	127.79
EBITDA Margin	11.75%	11.68%	10.74%	14.66%	14.35%	18.80%
D&A For EBITDA	46.4	46.16	45.21	34.75	30.91	28.1
EBIT	56.96	59	41.98	80.38	68.31	99.69
EBIT Margin	6.48%	6.55%	5.17%	10.24%	9.88%	14.67%
Effective Tax Rate	19.84%	19.04%	19.68%	14.81%	17.18%	14.60%
Revenue as Reported	879.6	900.77	812.13	785.19	691.57	679.7
Advertising Expenses	-	158.6	99.88	69.92	44.22	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.